Satio announced today that it completed a Small Business Innovation Research (SBIR) contract for its intradermal drug ...

Satio, Inc. is pleased to announce the successful completion of a Small Business Innovation Research contract awarded by the Advanced Research Projects Agency for Health (ARPA-H). The company's ground ...

Bydureon (exenatide), a weekly type 2 diabetes GLP-1 class injection, is nearing the end of its patent life and is also under threat from Novo Nordisk’s next-generation weekly jab, semaglutide.

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).